Literature DB >> 22503136

Affective symptoms and cognitive functions in Parkinson's disease.

Michele Poletti1, Anna De Rosa, Ubaldo Bonuccelli.   

Abstract

Patients with Parkinson's disease (PD) typically present with motor symptoms, but several non-motor symptoms, such as cognitive impairment, autonomic dysfunction and neuropsychiatric symptoms, are usually also present, when adequately looked for. The objective of this paper is to provide an up-to-date, comprehensive review of the influence of affective disorders, mainly depression and apathy, on cognitive functioning of PD patients. Reviewed empirical findings suggest that, although depression and apathy have differential neurobiological bases in PD, both are associated to an increased risk of cognitive impairment, especially of executive functions, in this clinical population. The potential influence of other affective disorders, as anxiety and alexithymia, on cognitive functioning of PD patients is actually almost unknown and needs further empirical investigation. The clinical implication of these findings is that the best assessment and management of PD patients should include both neuropsychological and neuropsychiatric evaluations and the presence of non-motor symptoms as cognitive disturbances and affective features should be investigated with patients and caregivers.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22503136     DOI: 10.1016/j.jns.2012.02.022

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  17 in total

1.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

2.  Computerized assessment of goal-directed behavior in Parkinson's disease.

Authors:  Whitney Fitts; Lauren Massimo; Nicholas Lim; Murray Grossman; Nabila Dahodwala
Journal:  J Clin Exp Neuropsychol       Date:  2016-06-07       Impact factor: 2.475

3.  Symptom Dimensions of Depression and Apathy and Their Relationship With Cognition in Parkinson's Disease.

Authors:  Sarah M Szymkowicz; Vonetta M Dotson; Jacob D Jones; Michael S Okun; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2017-10-16       Impact factor: 2.892

4.  Maladaptive avoidance patterns in Parkinson's disease are exacerbated by symptoms of depression.

Authors:  Jony Sheynin; Irina Baetu; Lyndsey E Collins-Praino; Catherine E Myers; Robyn Winwood-Smith; Ahmed A Moustafa
Journal:  Behav Brain Res       Date:  2020-01-11       Impact factor: 3.332

Review 5.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

6.  Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders.

Authors:  Stéphane Potvin; Ginette Aubin; Emmanuel Stip
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-06-13       Impact factor: 5.270

7.  Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease.

Authors:  Brian D Berman; Jason Smucny; Korey P Wylie; Erika Shelton; Eugene Kronberg; Maureen Leehey; Jason R Tregellas
Journal:  Mov Disord       Date:  2016-07-27       Impact factor: 10.338

8.  Mood Differences Among Parkinson's Disease Patients With Mild Cognitive Impairment.

Authors:  Jacob D Jones; Paul Mangal; Jacob Lafo; Michael S Okun; Dawn Bowers
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2016-01-21       Impact factor: 2.198

Review 9.  Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review.

Authors:  Michele Poletti; Ubaldo Bonuccelli
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

Review 10.  Neural and behavioral substrates of subtypes of Parkinson's disease.

Authors:  Ahmed A Moustafa; Michele Poletti
Journal:  Front Syst Neurosci       Date:  2013-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.